Clinical Trials Logo

Gastrointestinal Diseases clinical trials

View clinical trials related to Gastrointestinal Diseases.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT05918562 Enrolling by invitation - Clinical trials for Gastrointestinal Diseases

Efficacy of a Low Fiber Diet for Pediatric Colonoscopy Prep

Start date: April 20, 2021
Phase: N/A
Study type: Interventional

This study is designed to evaluate if pediatric patients who are undergoing a bowel preparation in anticipation of a colonoscopy may be able to take in a low fiber diet instead of a standard, clear liquid diet, while still accomplishing an adequate bowel prep.

NCT ID: NCT05889806 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)

Start date: May 10, 2023
Phase:
Study type: Observational

Study purpose: to explore the entire spectrum of proteomic and genomic changes (amongst others) involved in diseases and in healthy/control populations. The Study is designed to discover biomarkers, develop and validate diagnostic assays, instruments and therapeutics as well as other medical research. Specifically, researchers may analyze proteins, RNA, DNA copy number changes, including large and small (1,000-100,000 kb) scale rearrangements, transcription profiles, epigenetic modifications, sequence variation, and sequence in both diseased tissue and case-matched germline DNA from Subjects.

NCT ID: NCT05613153 Enrolling by invitation - Clinical trials for Bladder and Bowel Dysfunction

Peppermint Oil as a Treatment for Children With Bladder and Bowel Dysfunction

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to study the effect of peppermint oil in in children with bladder and bowel dysfunction. The main question it aims to answer is: Does peppermint oil improve symptoms of bladder and bowel dysfunction among children? Participants will: - Be provided peppermint oil capsules to be taken 3 times daily for 8 weeks. - At baseline and at a follow-up visit (8 weeks later), participants will be asked to complete the Vancouver Nonneurogenic Lower Urinary Tract Dysfunction/Dysfunctional Elimination Syndrome Questionnaire. Researchers will compare baseline and follow-up questionnaire data for each participant to determine if there is improvement in symptoms of bladder and bowel dysfunction.

NCT ID: NCT05501028 Enrolling by invitation - Clinical trials for Functional Gastrointestinal Disorders

NLP to Aid in the Evaluation and Diagnosis of FGIDs

Start date: August 9, 2018
Phase:
Study type: Observational

The study has two arms, where the same natural language processing (NLP) and probabilistic graphical modeling technology will be utilized on patients' report of symptoms in both arms. The clinical arm is focused on patients presenting for consultation with a gastroenterologist. The endoscopy arm is focused generally on patients presenting for a diagnostic endoscopy, with the goal of capturing Functional Gastrointestinal Disorder (FGID) patients prior to diagnosis.

NCT ID: NCT05298774 Enrolling by invitation - Clinical trials for Gastrointestinal Diseases

Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to determine if the myoelectrical measurements made by the G-Tech Wireless Patch System correlate with clinical markers of postoperative recovery such as passage of flatus/bowel movement, oral tolerance of diet and discharge readiness. Subsequently the data will be studied to establish which information in the signals is important in determining when to feed patients and possibly discharge them. These pilot prospective, open clinical studies suggests that myoelectrical activity, measured on the abdominal surface with a noninvasive wireless patch system, carries predictive value in determining time to feeding and time to flatus following open abdominal surgery. Having such information in advance of clinical measures could facilitate timely interventions, be it early feeding or delaying feeding as dictated by the patient's unique recovery profile. The G-Tech Wireless Patch System would provide a unique insight into the process allowing for a tailored protocol that could improve patient satisfaction and optimize recovery. The system could also enable feedback on the impact to the overall gastrointestinal myoelectrical activity of medications, particularly opioids, used for pain management that are known to inhibit gastrointestinal function by disrupting the normal recovery patterns of colonic motility.23-25 While it remains to be seen, in addition to predicting time to flatus/bowel movement early on, the ability to continue monitoring the patient may allow one to predict onset of secondary complications, such as wound infections or anastomotic leaks, that are associated with ileus. Similarly, given the wireless noninvasive nature of the system the patients could be discharged home with the patches, whereby they would serve as a remote monitoring tool. This could be particularly useful in cases where the patients may have been discharged early and may be at a high risk for readmission. The system would then send updates/alerts to the care team for management and potentially avoid preventable readmissions.

NCT ID: NCT05295446 Enrolling by invitation - Clinical trials for Functional Gastrointestinal Disorders

Functional GI Disease Registry

FGIDR
Start date: February 11, 2016
Phase:
Study type: Observational

The goal of this study is to establish a prospective observational cohort of individuals with functional GI disorders (functional constipation, irritable bowel syndrome, chronic nausea, functional diarrhea, and functional dyspepsia, as well as a subset of these individuals starting neuromodulation for their functional GI disorder) and collect clinical information and specimens. This information will be used in order to establish a patient registry with detailed clinical data and a specimen repository for future research as well as to specifically identify environmental, genetic, physiological, and psycho-social factors associated with functional GI disorders.

NCT ID: NCT05249270 Enrolling by invitation - Anxiety Clinical Trials

Online Parent-Report Evaluation of the Effects of Processed Music

Start date: March 22, 2020
Phase:
Study type: Observational

The study aims to examine effectiveness of the Safe and Sound Protocol (SSP) on sensory, digestive, and eating behaviors in children currently receiving therapy.

NCT ID: NCT05233631 Enrolling by invitation - Clinical trials for Gastrointestinal Disease

Therapeutic EUS Registry

T-EUS
Start date: June 12, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this prospective registry is to assess long-term data on efficacy, safety and clinical outcome of Therapeutic Endoscopic ultrasound (T-EUS) . The registry will evaluate technical feasibility, clinical outcome, safety profile and overall clinical management through medical chart review. The procedures we are evaluating are all clinically indicated and will not be prescribed to someone to participate in this research study.

NCT ID: NCT05115877 Enrolling by invitation - Clinical trials for Gastrointestinal Disease

Evaluation of Outcomes From Treatment of Benign or Malignant Gastrointestinal Diseases

Start date: January 7, 2021
Phase:
Study type: Observational

This study will be a retrospective, registry study collecting data of patients who were diagnosed with benign or malignant gastrointestinal diseases. Data will be collected from patient's chart retrospectively once the patients have completed proper treatment follow up with physicians' practice.

NCT ID: NCT05104723 Enrolling by invitation - Clinical trials for Chronic Granulomatous Disease

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

Start date: August 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Background: Chronic granulomatous disease (CGD) is a disease of the immune system, which is how the body fights germs. People with CGD get infections easily and have other health problems. Some medicines to treat CGD have a lot of side effects and do not always work. Researchers want to see if a new drug can help. Objective: To see if tofacitinib is safe to use for treating chronic CGD. Eligibility: Adults aged 18 and older with CGD who have not had success with other treatments and who are enrolled on NIH study # 93-I-0119. Design: Participants will be screened with the following: Physical exam Medical history Blood, urine, and stool tests Pregnancy test, if needed An upper gastrointestinal endoscopy and/or colonoscopy, if needed for their symptoms. Tissue samples will be collected. Skin assessment, if needed Participants will repeat some screening tests at visits. Participants will complete questionnaires about their general health and how CGD affects their daily life. Photographs will be taken of their skin, if needed. They will have lung function tests, if needed. They will have a computed tomography (CT) scan of the chest, abdomen, and pelvis, if needed. A CT scan uses X-rays to create pictures of the inside of the body. Participants will gradually reduce the amount of some CGD medicines they take. Then they will take tofacitinib as a pill twice a day or once a day for 3 months. They will keep a drug diary. They will have monthly study visits. They will have a follow-up visit about 1 month after their last study drug visit. Participation will last for about 6 months.